BioCentury | May 15, 2018
Distillery Therapeutics

Infectious disease

...could help prevent tuberculosis (TB). The fusion protein consists of five Mycobacterium tuberculosis antigens: fbpB, esxA...
...tuberculosis secreted antigen 85-B (fbpB; Ag85B); M. tuberculosis 6 kDa early secretory antigenic target (esxA; Esat6...
...A. Stanley, University of California Berkeley, Berkeley, Calif. email: sastanley@berkeley.edu Jennie Walters Aduro Biotech Inc. University of California Berkeley Mycobacterium tuberculosis 6 kDa early secretory antigenic target (esxA) (Esat6) Mycobacterium...
BioCentury | Feb 6, 2018
Distillery Therapeutics

Infectious disease

...help prevent tuberculosis (TB). The vaccine consists of six bacterial antigens -- M. tuberculosis fbpA, esxA...
...tuberculosis secreted antigen 85-A (fbpA; Ag85A); M. tuberculosis 6 kDa early secretory antigenic target (esxA; Esat6...
BioCentury | Mar 2, 2017
Translation in Brief

Polyester protection

...85-A ( fbpA ; Ag85A) and 6 kDa early secretory antigenic target ( esxA ; Esat6...
...a tuberculosis vaccine.” Applied and Environmental Microbiology (2017) --- Mary Romeo Mary Romeo AgResearch Ltd. Interferon (IFN) gamma Interleukin-17 (IL-17) Mycobacterium tuberculosis 6 kDa early secretory antigenic target (esxA) (Esat6) Mycobacterium...
BioCentury | Feb 2, 2015
Clinical News

H1/IC31: Phase II data

A double-blind, placebo-controlled, African Phase II trial in 48 antiretroviral-naïve HIV-infected adults ages 18-55 with CD4+ lymphocyte counts of >350/mm 3 showed that intramuscular H1/IC31 given on days 0 and 56 was well tolerated and...
BioCentury | Nov 18, 2013
Clinical News

AERAS-456: Phase I/IIa started

...Business: Infectious Molecular target: NA Description: Recombinant subunit vaccine containing TB antigens Ag85B , ESAT6...
BioCentury | Jan 16, 2012
Clinical News

Tuberculosis vaccine: Phase II started

...Business: Infectious Molecular target: Not applicable Description: Recombinant subunit vaccine containing TB antigens Ag85B and ESAT6...
BioCentury | Dec 12, 2011
Clinical News

IC31: Phase I started

Not-for-profit Aeras (Rockville, Md.) and Statens Serum Institut (Copenhagen, Denmark) said the South African Tuberculosis Vaccine Initiative (SATVI) began a South African Phase I trial to evaluate SSI H56-IC31 vaccine in 25 subjects with and...
BioCentury | Feb 17, 2011
Targets & Mechanisms

Protecting against latent TB

...Ag85B ) and M. tuberculosis 6 kDa early secretory antigenic target ( esxA ; Esat6...
...Next, the team generated a subunit vaccine dubbed H56. It is based on a trimeric Ag85B-Esat6-Rv2660c...
...than inoculation with BCG vaccine, the H1 vaccine or vaccines based on Rv2660c, Ag85B or Esat6...
BioCentury | Feb 3, 2011
Distillery Therapeutics

Indication: Infectious disease

...tuberculosis secreted antigen 85-B (fbpB; Ag85B); M. tuberculosis 6 kDa early secretory antigenic target (esxA; Esat6...
...includes the latency-associated Rv2660c protein could prevent TB. The vaccine (H56) is based on an Rv2660c-Ag85B-Esat6...
...provided greater protection from infection after bacterial challenge than a bacillus Calmette-Guérin (BCG) or an Ag85B-Esat6...
BioCentury | Mar 5, 2009
Targets & Mechanisms

Subunit boost for TB vaccines

...construct incorporating the M. tuberculosis proteins Ag85B (fbpB) and early secretory antigenic target 6 (esxA; Esat6...
Items per page:
1 - 10 of 12